Expert Series: Understanding TK2d and the KYGEVVI Approval
January 23 @ 12:00 pm – 1:00 pm EST
Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
This session will cover:
- The basics of TK2d, including its genetic cause, symptoms, and how it is diagnosed
- The impact of TK2d on patients and families
- An overview of KYGEVVI, including how it works and who may be eligible for treatment
- Important safety information and what to expect with therapy
For full prescribing information and important safety details, please visit https://www.kygevvi.com/.
About the Speaker
Sarah Chang, PhD
Sarah Chang, PhD, is Medical Strategy Lead at UCB, where she works on the thymidine kinase 2 deficiency (TK2d) program. TK2d is a rare, life-threatening mitochondrial disease caused by changes in the TK2 gene. Sarah focuses on helping doctors recognize TK2d earlier and improving the path to diagnosis, so patients can get the care they need as soon as possible. She believes that every person—no matter how rare their condition—deserves timely care, meaningful support, and hope for a better future.
